세계의 벡티빅스(Vectibix, panitumumab) 시장 보고서 : 역학, 파이프라인 분석, 시장 인사이트 및 예측(2025년)

Vectibix (panitumumab) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

US $ 4,490 ￦ 6,290,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,091,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,893,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

벡티빅스(Vectibix, panitumumab) 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 8%로 성장할 전망이며, 18억 5,390만 달러로 성장이 예측됩니다. 예측 기간의 성장은 전이성 결장직장암(mcrc)의 세계 유병률 증가, 맞춤형 의료에 대한 관심 고조, 신흥시장에서의 헬스케어 지출 증가, 종양학에서의 생물제제 채택 확대, 환자의 QOL에 대한 관심 고조 등에 기인할 것으로 보입니다. 예측 기간 주요 동향으로는 항EGFR 요법의 진보, 제약 기업 간의 제휴 및 공동 연구, 선진 진단 툴의 통합, 동반 진단약의 개발, 차세대 시퀀서의 채용 등을 들 수 있습니다.

대장암의 유병률 증가는 향후 수년간 벡티빅스(Vectibix, panitumumab) 시장의 성장을 견인할 것으로 예측됩니다. 결장이나 직장에서 시작되는 대장암은 노화, 유전적 소인, 환경의 영향 등의 요인에 영향을 받습니다. 대장암의 이환율 상승은 인구의 고령화, 생존율의 향상, 검출 방법의 개선과 관련이 있습니다. 모노클로날 항체인 벡티빅스(파니툼맙)는 상피성장인자수용체(EGFR)를 표적으로 저해해 야생형 KRAS 종양 환자의 종양 성장과 진행을 늦춥니다. 이것은 기존 화학요법에 반응하지 않는 환자에 대한 효과적인 치료법입니다. 세계보건기구(WHO)에 따르면 대장암의 세계 부담은 2040년까지 큰 폭으로 증가해 연간 320만 명이 새로 이환될 것으로 예상되고 있으며, 이는 63%의 증가입니다. 이러한 유병률의 증가는 벡티빅스의 수요를 견인하게 될 것으로 생각됩니다.

맞춤형 의료에 대한 수요 증가는 벡티빅스(Vectibix, panitumumab) 시장의 성장을 가속하는 중요한 요인입니다. 맞춤형 의료는 유전자 프로파일을 포함한 개별 환자의 특성에 따라 치료를 조정하는 것입니다. 게놈 기술의 진보, 분자생물학에 대한 이해의 향상, 정밀 진단 도구의 이용 가능성에 의해 개별화 치료는 보다 일반적인 것이 되고 있습니다. 벡티빅스는 특히 종양이 야생형 EGFR을 발현하고 있는 환자에서 암세포상의 EGFR을 표적으로 함으로써 전이성 대장암의 맞춤형 치료로 사용됩니다. 이 표적 접근법은 치료 효과를 높이고 부작용을 최소화합니다. 예를 들어 2023년 2월 맞춤형 의료연합은 FDA가 체외 진단검사의 몇 가지 중요한 적응증을 승인했다는 점을 강조하며 맞춤형 의료 수요를 높이는 데 기여하고 있습니다. 이 동향은 벡티빅스 시장의 성장을 더욱 뒷받침합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 바이오의약품 시장에서의 제품 특성

• 분자 유형
• 투여 경로(ROA)
• 작용기전(MOA)
• 안전성 및 유효성

제4장 시장 동향 및 전략

제5장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제6장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 벡티빅스(Vectibix, panitumumab) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 벡티빅스(Vectibix, panitumumab) 시장 : 성장률 분석
• 세계의 벡티빅스(Vectibix, panitumumab) 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 벡티빅스(Vectibix, panitumumab) 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 벡티빅스(Vectibix, panitumumab) : 전체 시장 규모(TAM)

제7장 세계의 시장 가격 분석 및 예측

제8장 시장 세분화

• 세계의 벡티빅스(Vectibix, panitumumab) 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 온라인 약국
• 세계의 벡티빅스(Vectibix, panitumumab) 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 대장암 치료
• 기타 암 치료
• 세계의 벡티빅스(Vectibix, panitumumab) 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 클리닉
• 외래수술센터(ASC)

제9장 세계의 임상적응증 시장 역학

• 약제의 부작용
• 임상적응증의 발병률 및 유병률

제10장 지역별 및 국가별 분석

• 세계의 벡티빅스(Vectibix, panitumumab) 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 벡티빅스(Vectibix, panitumumab) 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 경쟁 구도 및 기업 프로파일

• 벡티빅스(Vectibix, panitumumab) 시장 : 경쟁 구도
• 벡티빅스(Vectibix, panitumumab) 시장 : 기업 프로파일
  • Amgen Inc.

제29장 세계 시장 : 파이프라인 분석

제30장 세계 시장 경쟁 벤치마킹 및 대시보드

제31장 주요 인수 합병(M&A)

제32장 최근 시장 동향

제33장 시장의 잠재력이 높은 국가, 부문 및 전략

• 벡티빅스(Vectibix, panitumumab) 시장(2029년) : 새로운 기회를 제공하는 국가
• 벡티빅스(Vectibix, panitumumab) 시장(2029년) : 새로운 기회를 제공하는 부문
• 벡티빅스(Vectibix, panitumumab) 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제34장 부록

AJY

영문 목차

영문목차

Vectibix (panitumumab) is a monoclonal antibody used to treat metastatic colorectal cancer (mCRC). It targets the epidermal growth factor receptor (EGFR), a protein found on the surface of certain cancer cells. By binding to EGFR, panitumumab prevents its activation by natural growth factors, thereby inhibiting the signaling pathways that promote cell division and tumor growth.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The key distribution channels for vectibix include hospital pharmacies and online pharmacies. Hospital pharmacies provide medications to both inpatients and outpatients within healthcare facilities as part of integrated medical care. The drug is primarily used for treating colorectal cancer and other cancer types, with end-users including hospitals, clinics, and ambulatory surgical centers.

The vectibix (panitumumab) market research report is one of a series of new reports from The Business Research Company that provides vectibix (panitumumab) market statistics, including vectibix (panitumumab) industry global market size, regional shares, competitors with a vectibix (panitumumab) market share, detailed vectibix (panitumumab) market segments, market trends and opportunities, and any further data you may need to thrive in the vectibix (panitumumab) industry. This vectibix (panitumumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vectibix (panitumumab) market size is expected to see strong growth in the next few years. It will grow to $1,853.9 million in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to increasing prevalence of metastatic colorectal cancer (mcrc) globally, growing focus on personalized medicine, increasing healthcare spending in emerging markets, growing adoption of biologics in oncology, increasing focus on patient quality of life. Major trends in the forecast period include advancements in anti-EGFR therapies, partnerships and collaborations between pharmaceutical companies, integration of advanced diagnostic tools, development of companion diagnostics, adoption of next-generation sequencing.

The increasing prevalence of colorectal cancer is expected to drive the growth of the vectibix (panitumumab) market in the coming years. Colorectal cancer, which begins in the colon or rectum, is influenced by factors such as aging, genetic predispositions, and environmental influences. The rising incidence of colorectal cancer is linked to an aging population, better survival rates, and improved detection methods. Vectibix (panitumumab), a monoclonal antibody, targets and inhibits the epidermal growth factor receptor (EGFR) to slow tumor growth and progression in patients with wild-type KRAS tumors. This offers an effective treatment for patients who do not respond to conventional chemotherapy. According to the World Health Organization (WHO), the global burden of colorectal cancer is expected to increase significantly by 2040, with 3.2 million new cases annually, a 63% rise. This growing prevalence is poised to drive the demand for vectibix.

The rising demand for personalized medicine is a key factor propelling the growth of the vectibix (panitumumab) market. Personalized medicine tailors treatments based on individual patient characteristics, including genetic profiles. Advances in genomic technologies, improved understanding of molecular biology, and the availability of precision diagnostic tools have made personalized therapies more common. Vectibix is used as a personalized treatment for metastatic colorectal cancer by targeting the EGFR on cancer cells, particularly in patients whose tumors express wild-type EGFR. This targeted approach improves therapeutic efficacy and minimizes side effects. For example, in February 2023, the Personalized Medicine Coalition highlighted that the FDA approved several important indications for in vitro diagnostic testing, contributing to the rising demand for personalized medicine. This trend further supports the growth of the vectibix market.

A significant trend in the vectibix market is the development of molecular diagnostic products, such as companion diagnostic kits, which help identify the most suitable patients for targeted therapies. Companion diagnostic kits detect specific biomarkers or genetic mutations, ensuring that treatments like Vectibix are given to patients who are most likely to benefit. In October 2023, EntroGen Inc. received FDA approval for the CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix. This kit, which detects mutations in KRAS and NRAS genes, helps clinicians identify patients who would benefit from Vectibix, ensuring more effective treatment while minimizing unnecessary side effects and costs. This trend towards personalized diagnostics is enhancing the precision of Vectibix therapy and contributing to the market's growth.

The Key player operating in the vectibix (panitumumab) market is Amgen Inc.

North America was the largest region in the vectibix (panitumumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vectibix (panitumumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vectibix (panitumumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vectibix (panitumumab) market consists of sales of chemotherapy combination products, nutritional supplements, supportive care medications and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vectibix (panitumumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vectibix (panitumumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vectibix (panitumumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vectibix (panitumumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Distribution Channel: Hospital Pharmacies; Online Pharmacies
• 2) By Application: Colorectal Cancer Treatment; Other Cancer Treatments
• 3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers
• Companies Mentioned: Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vectibix (panitumumab) Market Characteristics

3. Vectibix (panitumumab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Vectibix (panitumumab) Market Trends And Strategies

5. Vectibix (panitumumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Vectibix (panitumumab) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Vectibix (panitumumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Vectibix (panitumumab) Market Growth Rate Analysis
• 6.4. Global Vectibix (panitumumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Vectibix (panitumumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Vectibix (panitumumab) Total Addressable Market (TAM)

7. Global Vectibix (panitumumab) Market Pricing Analysis & Forecasts

8. Vectibix (panitumumab) Market Segmentation

• 8.1. Global Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• 8.2. Global Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Colorectal Cancer Treatment
• Other Cancer Treatments
• 8.3. Global Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Surgical Centers

9. Global Vectibix (panitumumab) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Vectibix (panitumumab) Market Regional And Country Analysis

• 10.1. Global Vectibix (panitumumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Vectibix (panitumumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Vectibix (panitumumab) Market

• 11.1. Asia-Pacific Vectibix (panitumumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Vectibix (panitumumab) Market

• 12.1. China Vectibix (panitumumab) Market Overview
• 12.2. China Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Vectibix (panitumumab) Market

• 13.1. India Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Vectibix (panitumumab) Market

• 14.1. Japan Vectibix (panitumumab) Market Overview
• 14.2. Japan Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Vectibix (panitumumab) Market

• 15.1. Australia Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Vectibix (panitumumab) Market

• 16.1. South Korea Vectibix (panitumumab) Market Overview
• 16.2. South Korea Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Vectibix (panitumumab) Market

• 17.1. Western Europe Vectibix (panitumumab) Market Overview
• 17.2. Western Europe Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Vectibix (panitumumab) Market

• 18.1. UK Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Vectibix (panitumumab) Market

• 19.1. Germany Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Vectibix (panitumumab) Market

• 20.1. France Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vectibix (panitumumab) Market

• 21.1. Eastern Europe Vectibix (panitumumab) Market Overview
• 21.2. Eastern Europe Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Vectibix (panitumumab) Market

• 22.1. North America Vectibix (panitumumab) Market Overview
• 22.2. North America Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Vectibix (panitumumab) Market

• 23.1. USA Vectibix (panitumumab) Market Overview
• 23.2. USA Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Vectibix (panitumumab) Market

• 24.1. Canada Vectibix (panitumumab) Market Overview
• 24.2. Canada Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Vectibix (panitumumab) Market

• 25.1. South America Vectibix (panitumumab) Market Overview
• 25.2. South America Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Vectibix (panitumumab) Market

• 26.1. Middle East Vectibix (panitumumab) Market Overview
• 26.2. Middle East Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Vectibix (panitumumab) Market

• 27.1. Africa Vectibix (panitumumab) Market Overview
• 27.2. Africa Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Vectibix (panitumumab) Market Competitive Landscape And Company Profiles

• 28.1. Vectibix (panitumumab) Market Competitive Landscape
• 28.2. Vectibix (panitumumab) Market Company Profiles
  • 28.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

29. Global Vectibix (panitumumab) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Vectibix (panitumumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Vectibix (panitumumab) Market

32. Recent Developments In The Vectibix (panitumumab) Market

33. Vectibix (panitumumab) Market High Potential Countries, Segments and Strategies

• 33.1 Vectibix (panitumumab) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Vectibix (panitumumab) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Vectibix (panitumumab) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer